返回 
加入收藏
贵州省医药产业发展现状调查及对策研究
x
请在关注微信后，向客服人员索取文件
| 篇名： | 贵州省医药产业发展现状调查及对策研究 |
| TITLE： | |
| 摘要： | 目的：为实现贵州省医药产业的可持续发展提供参考。方法：采用文献查阅、个人访谈及问卷调查等方法相结合，对贵州省医药产业发展现状进行调查和分析，进而针对存在的不足提出相应对策建议。结果：文献查阅范围包括通过百度搜索引擎获得的网络文献，政府行政部门门户网站发布的资料、文件以及中国知网、维普数据库收录的文献；个人访谈涉及贵州省食品药品监督管理局政策法规处、药品化妆品生产监管处、医疗器械监管处的5名相关管理人员；问卷调查（对象为药品生产企业）共发放问卷70份，回收有效问卷57份，有效回收率为81.4％。贵州省目前共有药品生产企业175家（有56.5％集中在贵阳市），医疗器械生产企业106家；57家受访药品生产企业中通过2010版《药品生产质量管理规范》（GMP）认证的占87.8％。贵州省中药材品种数居全国第2位，2015年中药材人工种植及野生保护抚育总面积居全国第3位，中成药工业产值占全省医药工业总产值的85.1％，但获得审批的新药中无1、2类新药、研发人员中高学历层次人才明显偏少；化学药产业的产出能力远低于全国平均水平，化学药工业产值仅占全省医药工业总产值的10％左右，且由药品生产企业主持申报的新药近年获批成功率几乎为零；生物制品产业为新兴产业，目前仅有3家生物制品生产企业；医疗器械产业生产的341个产品中Ⅰ类146个、Ⅱ类190个、Ⅲ类5个，覆盖范围较窄，生产种类较少，整体水平在全国相对落后；医药衍生品产业已有7.0％的受访药品生产企业涉足，且中医药保健养生业的发展越来越受到重视。结论：贵州省医药产业以中药民族药产业为主导，化学药、生物制品、医疗器械产业发展滞后，医药衍生品产业需更好地促进中医药与健康养生的融合；产业整体战略意识较落后，高端研发人才较缺乏，自主创新能力较弱。建议进行顶层设计，引导企业兼并、重组；发展特色医药，深度扶持小分子化学药和生物制品生产企业；深化产业政策理解，加大自主创新投入；开发新医药衍生产品，拓展医药电子商务销售渠道；拓宽产业链深度、广度和宽度，挖掘医药大数据。 |
| ABSTRACT： | OBJECTIVE： To provide reference for the sustainable development of pharmaceutical industry in Guizhou province. METHODS： By literature review， personal interview and questionnaire survey， the current situation about the development of pharmaceutical industry in Guizhou province were investigated and analyzed， and the corresponding countermeasures and suggestions were put forward. RESULTS： The literatures were obtained from network literature by Baidu search engine， published data by government portal website of administrative department， documents by CNKI and VIP. Five personal interviews involved the relevant management personnel in Policies and Regulations Department， Medicine and Cosmetics Production Supervision Department， Medical Device Supervision Department of Guizhou Province Food and Drug Administration. A total of 70 questionnaires （drug production enterprises as object） were sent out， and 57 valid questionnaires were collected with the effective recovery rate of 81.4％. In the present， there were a total of 175 pharmaceutical production enterprises （56.5％ in Guiyang city） and 106 medical device manufacturers in Guizhou province. Of 57 pharmaceutical manufacturing enterprises investigated， 87.8％ of them were certified by the 2010 edition of Good Manufacturing Practice （GMP）. The number of varieties of Chinese herbal medicines in Guizhou province ranked second in the whole country； total area of Chinese herbal medicine planting， wild protection and tending ranked third in the whole country in 2015； the industrial output value of Chinese patent medicine accounted for 85.1％ of the total output value of the pharmaceutical industry； but no approved new medicines were class 1 and 2 new medicines； R&D personnel with high education levels took small proportion significantly. The output capacity of chemical medicine industry was far lower than the average national level； the chemical industry output value accounted for only about 10％ of the total output value of the pharmaceutical industry in the province； the rate of success approval was almost zero for new drugs declared by drug manufacturers in recent years. Biological products industry was an emerging industry， currently there were only 3 biological products production enterprises. Of 341 products in medical device industry， there were 146 classⅠproducts， 190 classⅡproducts and 5 classⅢproducts， manifesting as narrow coverage， few production type， relatively backward level. Seven percent of pharmaceutical production enterprise involved in the derivatives industry， and the development of TCM health care industry attracted more and more attention. CONCLUSIONS： The Chinese and national medicine industry has been the dominant force， the development of chemical medicine， biological products and medical device industry has lagged behind， and medicine derivatives industry needs to promote the integration of TCM and health-and-fitness. The whole industry strategic consciousness is comparatively backward， high-end R&D personnel is lack， and independent innovation ability is weak. It is suggested to done the top design， guide enterprises mergers and restructuring； develop characteristic medicine， support small molecule chemical medicines and biological products enterprises deeply； deepen the understanding of industrial policy， and increase investment in independent innovation； develop new medicine derivatives， and expand the pharmaceutical e-commerce sales channel； broaden the industry chain depth， breadth and width， and excavate medical big data. |
| 期刊： | 2017年第28卷第30期 |
| 作者： | 周戈耀，陈文佼，田海玉，孟小夏，禄晓龙 |
| AUTHORS： | ZHOU Geyao，CHEN Wenjiao，TIAN Haiyu，MENG Xiaoxia，LU Xiaolong |
| 关键字： | 贵州省；医药产业；发展现状；调查；对策 |
| KEYWORDS： | Guizhou province； Pharmaceutical industry； Development situation； Investigation； Countermeasures |
| 阅读数： | 1474 次 |
| 本月下载数： | 36 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
